Efficacy of eplerenone added to renin-angiotensin blockade in elderly hypertensive patients: The Jichi-Eplerenone Treatment (JET) study

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 12, Issue 3, 2011, Pages 340-347

  Yano, Yuichiro ^a,b   Hoshide, Satoshi ^b   Tamaki, Noboru ^c   Nagata, Masahiko ^d   Sasaki, Kouji ^e   Kanemaru, Yoshimasa ^a   Shimada, Kazuyuki ^b   Kario, Kazuomi ^b  

^a Saigo National Health Insurance Hospital   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c Tamaki Clinic   (Japan)

^d Kijo Clinic   (Japan)

^e Sasaki Clinic   (Japan)

Author keywords

24 h blood pressure; Eplerenone; plasminogen activator inhibitor 1; procollagen type III aminoterminal peptide; urinary albumin excretion

Indexed keywords

ALBUMIN; ALDOSTERONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CARBOXY TERMINAL TELOPEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; RENIN; SPIRONOLACTONE; TRIACYLGLYCEROL;

AGED; ARTICLE; BLOOD PRESSURE MONITORING; CASE REPORT; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DRUG DOSE INCREASE; DRUG TOLERABILITY; FEMALE; GERIATRIC PATIENT; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; INSULIN BLOOD LEVEL; LOW DRUG DOSE; MALE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; URINARY EXCRETION;

AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; FEMALE; HEMOSTASIS; HUMANS; HYPERTENSION; JAPAN; MALE; PEPTIDE FRAGMENTS; PROCOLLAGEN; RENIN; RENIN-ANGIOTENSIN SYSTEM; SPIRONOLACTONE; TIME FACTORS; TREATMENT OUTCOME;

EID: 80052388712     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320310390404     Document Type: Article

References (38)

1. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R. and Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000 ; 342: 145-153.
2. Dahlöf B., Devereux RB, Kjeldsen SE, Julius S., Beevers G., de Faire U., Fyhrquist F., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002 ; 359: 995-1003. (Pubitemid 34286536)
3. Ogihara T., Kikuchi K., Matsuoka H., Fujita T., Higaki J., Horiuchi M., et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 2009 ; 32: 3-107.
4. Ishikawa J., Kario K., Hoshide S., Eguchi K., Morinari M., Kaneda R., et al. Determinants of exaggerated difference in morning and evening blood pressure measured by self-measured blood pressure monitoring in medicated hypertensive patients: Jichi Morning Hypertension Research (J-MORE) Study. Am J Hypertens 2005 ; 18: 958-965. (Pubitemid 41040267)
5. Mori H., Ukai H., Yamamoto H., Saitou S., Hirao K., Yamauchi M., et al. Current status of antihypertensive prescription and associated blood pressure control in Japan. Hypertens Res 2006 ; 29: 143-151.
6. Braunwald E., Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J., et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004 ; 351: 2058-2068.
7. Massie BM, Carson PE, McMurray JJ, Komajda M., McKelvie R., Zile MR, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008 ; 359: 2456-2467.
8. Sato A., Hayashi K., Naruse M. and Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003 ; 41: 64-68. (Pubitemid 36056793)
9. Bomback AS and Klemmer PJ The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 2007 ; 3: 486-492. (Pubitemid 47313030)
10. Krum H., Nolly H., Workman D., He W., Roniker B., Krause S., et al. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 2002 ; 40: 117-123. (Pubitemid 34840085)
11. Brown NJ, Agirbasli MA, Williams GH, Litchfield WR and Vaughan DE Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1. Hypertension 1998 ; 32: 965-971. (Pubitemid 29001421)
12. Sawathiparnich P., Kumar S., Vaughan DE and Brown NJ Spironolactone abolishes the relationship between aldosterone and plasminogen activator inhibitor-1 in humans. J Clin Endocrinol Metab 2002 ; 87: 448-452. (Pubitemid 34158202)
13. Rocha R. and Funder JW The pathophysiology of aldosterone in the cardiovascular system. Ann N Y Acad Sci 2002 ; 970: 89-100. (Pubitemid 35286086)
14. Hollenberg NK Aldosterone in the development and progression of renal injury. Kidney Int 2004 ; 66: 1-9. (Pubitemid 38870076)
15. Imai E., Horio M., Nitta K., Yamagata K., Iseki K., Tsukamoto Y., et al. Modification of the Modification of Diet in Renal Disease (MDRD) Study equation for Japan. Am J Kidney Dis 2007 ; 50: 927-937. (Pubitemid 350130278)
16. Nishizaka MK, Zaman MA and Calhoun DA Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003 ; 16: 925-930. (Pubitemid 37315491)
17. Kario K., Pickering TG, Matsuo T., Hoshide S., Schwartz JE and Shimada K. Stroke prognosis and abnormal nocturnal blood pressure falls in older hypertensives. Hypertension 2001 ; 38: 852-857. (Pubitemid 34258682)
18. Klappacher G., Franzen P., Haab D., Mehrabi M., Binder M., Plesch K., et al. Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis. Am J Cardiol 1995 ; 75: 913-918.
19. Tsutamoto T., Wada A., Maeda K., Mabuchi N., Hayashi M., Tsutsui T., et al. Spironolactone inhibits the transcardiac extraction of aldosterone in patients with congestive heart failure. J Am Coll Cardiol 2000 ; 36: 838-844.
20. Querejeta R., Varo N., López B., Larman M., Artiñano E., Etayo JC, et al. Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation 2000 ; 101: 1729-1735. (Pubitemid 30196635)
21. Boomsma F. and van den Meiracker AH Plasma A- and B-type natriuretic peptides: physiology, methodology and clinical use. Cardiovasc Res 2001 ; 51: 442-449. (Pubitemid 32718592)
22. Nagata K., Obata K., Xu J., Ichihara S., Noda A., Kimata H., et al. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension 2006 ; 47: 656-664. (Pubitemid 43740235)
23. Hoshide S., Kario K., Hoshide Y., Umeda Y., Hashimoto T., Kunii O., et al. Associations between nondipping of nocturnal blood pressure decrease and cardiovascular target organ damage in strictly selected community-dwelling normotensives. Am J Hypertens 2003 ; 16: 434-438. (Pubitemid 36667796)
24. Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, Pimenta E., Aban I., Oparil S., et al. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med 2008 ; 168: 1159-1164. (Pubitemid 351831398)
25. Uzu T. and Kimura G. Diuretics shift circadian rhythm of blood pressure from nondipper to dipper in essential hypertension. Circulation 1999 ; 100: 1635-1638. (Pubitemid 29477273)
26. Uzu T., Harada T., Namba T., Yamamoto R., Takahara K., Yamauchi A., et al. Thiazide diuretics enhance nocturnal blood pressure fall and reduce proteinuria in immunoglobulin A nephropathy treated with angiotensin II modulators. J Hypertens 2005 ; 23: 861-865. (Pubitemid 40523286)
27. Williams GH, Burgess E., Kolloch RE, Ruilope LM, Niegowska J., Kipnes MS, et al. Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am J Cardiol 2004 ; 93: 990-996. (Pubitemid 38479452)
28. Levy DG, Rocha R. and Funder JW Distinguishing the antihypertensive and electrolyte effects of eplerenone. J Clin Endocrinol Metab 2004 ; 89: 2736-2740. (Pubitemid 38766358)
29. Brown NJ, Kumar S., Painter CA and Vaughan DE ACE inhibition versus angiotensin type 1 receptor antagonism: differential effects on PAI-1 over time. Hypertension 2002 ; 40: 859-865. (Pubitemid 35434907)
30. Sawathiparnich P., Murphey LJ, Kumar S., Vaughan DE and Brown NJ Effect of combined AT1 receptor and aldosterone receptor antagonism on plasminogen activator inhibitor-1. J Clin Endocrinol Metab 2003 ; 88: 3867-3873. (Pubitemid 37034540)
31. Zannad F., Dousset B. and Alla F. Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship. Hypertension 2001 ; 38: 1227-1232. (Pubitemid 34252836)
32. MacFadyen RJ, Barr CS and Struthers AD Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res 1997 ; 35: 30-34. (Pubitemid 27374737)
33. López B., Querejeta R., Varo N., González A., Larman M., Martínez Ubago JL, et al. Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients. Circulation 2001 ; 104: 286-291. (Pubitemid 32666949)
34. Funder JW Aldosterone and mineralocorticoid receptors in the cardiovascular system. Prog Cardiovasc Dis 2010 ; 52: 393-400.
35. Funder JW The role of aldosterone and mineralocorticoid receptors in cardiovascular disease. Am J Cardiovasc Drugs 2007 ; 7: 151-157. (Pubitemid 47047985)
36. Mihailidou AS, Loan Le TY, Mardini M. and Funder JW Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction. Hypertension 2009 ; 54: 1306-1312.
37. Bomback AS, Kshirsagar AV, Amamoo MA and Klemmer PJ Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Am J Kidney Dis 2008 ; 51: 199-211.
38. Hermida RC, Calvo C., Ayala DE and López JE Decrease in urinary albumin excretion associated with the normalisation of nocturnal blood pressure in hypertensive subjects. Hypertension 2005 ; 46: 960-968.